Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix (Nasdaq: PULM) reported 2Q 2026 results and updated investors on its proposed merger with privately held Eos SENOLYTIX. Pulmatrix filed an S-4 and said the deal is expected to close in 3Q 2026. It raised $1.0 million via a private placement. Cash was $2.2 million at June 30, 2026.

Original reporting
Published Aug 13, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger — source image
Decision brief

The 30-second read

$PULMNeutralMed
01

Why it matters

The S-4 filing and Q2 liquidity/cost disclosures update the probability-weighted path to a Q3 2026 close, while paused clinical development increases reliance on licensing/monetization and deal completion.

02

Market read

Traders can reassess merger-close timing and financing risk using the new S-4 filing and updated cash runway language, alongside Q2 expense reductions.

03

What to watch

Cash is tight ($2.2M plus restricted cash) and the going-concern assumption plus paused development can dominate valuation even if the merger advances.

Relevance 7/10Novelty 6/10Timing: today, after-hours PR with S-4 filing and Q2 2026 financial update

Background

Pulmatrix is a small-cap inhaled therapeutics company using iSPERSE technology and announced a merger agreement with privately held Eos SENOLYTIX in March 2026.

Company-level read

Ticker impact

$PULMNeutralMedium confidence
Context

Pulmatrix filed an S-4 for its proposed merger with Eos SENOLYTIX and reported Q2 2026 results while clinical development is on hold.

Expected impact

Likely two-way volatility around merger-S-4 progress and any subsequent SEC/closing-condition updates; fundamentals are constrained by low cash and paused clinical work.

Evidence & confidence

The article provides primary disclosures (S-4 filing, Q2 cash and expense levels, going-concern framing, and merger timing target for Q3 2026) but no new efficacy/approval catalyst.

Market effects

Biopharma M&A and inhaled drug delivery peers may see sentiment spillover, but the disclosure is company-specific.

Limited, primarily affects US small-cap biotech risk appetite.

Low; India PUR1900 Phase 3 progression is partner-led and not a broad global catalyst.

Counterpoint

The merger is still subject to customary closing conditions, and the company’s clinical pipeline is on hold, so the S-4 may not translate into near-term value creation.

Key entities

  • Pulmatrix, Inc.

    Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and S-4 progress toward a merger with Eos SENOLYTIX.

  • Eos SENOLYTIX, Inc.

    Privately held biotech developing gerotherapeutic peptides via the MitoXcel platform; merger counterparty.

  • Cipla Technologies

    Partner expected to commence Phase 3 in India for PUR1900 and share monetization economics with Pulmatrix.

  • MannKind Corporation

    Licensee of iSPERSE technology in certain fields of use.

Related articles

$PULMMed

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut

$PULMMedAI 8/10

Eos reports early rat study data for aging drug candidate

Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.

$PULMMed

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm

$ITGRHighAI 9/10

Integer Secures $2.45 Billion Credit Facility to Finance $5.4 Billion Merger

Integer Holdings (ITGR) secured a $2.45 billion credit facility, including a $2.1 billion term loan and up to $350 million revolving credit, to finance a $5.4 billion merger. The company also amended its 2028 and 2030 convertible notes to reflect a $127-per-share cash consideration. Integer repaid and terminated its 2021 credit agreement and capped call transactions related to both note issues, with undisclosed cash payments received.